Sparsentan Suppliers & Bulk Manufacturers

Sparsentan is used to treat rare kidney diseases such as IgA nephropathy and focal segmental glomerulosclerosis (FSGS). It helps reduce proteinuria (excess protein in the urine) and slows the progression of kidney damage. Sparsentan works by blocking two key pathways involved in kidney injury — endothelin type A and angiotensin II type 1 receptors — offering dual protection to the kidneys.

Sparsentan is made from the active ingredient sparsentan, a dual-acting angiotensin II and endothelin receptor antagonist. Its chemical name is (2E)-3-[2-butyl-1-[(4′-carboxy[1,1′-biphenyl]-4-yl)methyl]-7-(2-methylpropyl)-2,6-dioxo-1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-yl]-N-(2-hydroxy-2-phenylethyl)acrylamide. It is formulated with excipients such as lactose monohydrate, cellulose, and magnesium stearate depending on the dosage form.

The trade name of sparsentan is Filspári in the United States and Kinpeygo in the European Union.

Sparsentan (Filspári/Kinpeygo) is developed and marketed by Travere Therapeutics in the United States and by CSL Vifor in Europe under a licensing agreement.

The generic name of the drug is sparsentan.

The brand names of sparsentan are Filspári (USA) and Kinpeygo (EU).

Sparsentan is manufactured in the United States by Travere Therapeutics and in Europe by CSL Vifor, with global distribution to markets where treatment for IgA nephropathy and FSGS is approved.